Consensus ResMed, Inc.

Equities

RMD

US7611521078

Advanced Medical Equipment & Technology

Real-time Estimate Cboe BZX Other stock markets 12:34:00 13/12/2025 am IST			5-day change	1st Jan Change
250.70 ^USD	-0.67%		-2.07%	+9.86%

10/12	Resmed Insider Sold Shares Worth $1,254,796, According to a Recent SEC Filing	MT
09/12	Shares of Resmed Fall After Securing FDA Clearance for a Device Recommending Personalized Comfort Settings	MT

Evolution of the Average Target: ResMed, Inc.

Evolution of the Target Price: ResMed, Inc.

Changes in Analyst Recommendations: ResMed, Inc.

9d3a0aea1.CFAHtOGaLwql9eofCnag1PvsvV-bAnw8u746pqjYPPc.YDlMzaX1WFnpkttFbEfX4bC71BrQe05ry_le1tCRV6cwMUnSmKJLM-O4uw~f2028d308dda21288dbb999b6ce18228

Analysts' recommendations: ResMed, Inc.

31/10	Baird Adjusts Price Target on ResMed to $300 From $320	MT
31/10	Jefferies & Co Adjusts ResMed Price Target to $285 From $290	MT
31/10	Wells Fargo Adjusts ResMed Price Target to $265 From $280	MT
31/10	Wolfe Research Adjusts ResMed Price Target to $225 From $215	MT
31/10	Morgan Stanley Adjusts ResMed Price Target to $305 From $304	MT
31/10	Mizuho Adjusts Price Target on ResMed to $300 From $310	MT
31/10	KeyBanc Adjusts Price Target on ResMed to $299 From $298	MT
31/10	RBC Lifts Price Target on ResMed to $303 From $300, Keeps Outperform Rating	MT
31/10	Morgan Stanley Lifts Price Target on ResMed to $305 From $304, Keeps Overweight Rating	MT
21/10	Morgan Stanley Adjusts Price Target on ResMed to $304 From $298, Maintains Overweight Rating	MT
15/10	Baird Adjusts Price Target on ResMed to $320 From $305, Maintains Outperform Rating	MT
14/10	Mizuho Adjusts Price Target on ResMed to $310 From $290, Maintains Outperform Rating	MT
14/10	PolyNovo Limited Announces Appointment of Robert Douglas to the Board of Directors	CI
18/09	Analyst recommendations: Autozone, Crowdstrike, Deere & Company, Micron Technology, MongoDB...
18/09	Citigroup Initiates ResMed at Buy With $330 Price Target	MT
18/08	CICC Adjusts Price Target on ResMed to $325 From $295, Maintains Outperform Rating	MT
01/08	JPMorgan Adjusts ResMed Price Target to $310 From $290, Maintains Overweight Rating	MT
01/08	Baird Adjusts ResMed Price Target to $305 From $283, Maintains Outperform Rating	MT
01/08	UBS Adjusts ResMed Price Target to $325 From $285, Maintains Buy Rating	MT
01/08	Piper Sandler Adjusts Price Target on ResMed to $270 From $248, Maintains Neutral Rating	MT
01/08	Stifel Adjusts Price Target on ResMed to $270 From $240, Maintains Hold Rating	MT
01/08	KeyBanc Adjusts Price Target on ResMed to $298 From $274, Maintains Overweight Rating	MT
01/08	Jefferies Adjusts Price Target on ResMed to $290 From $245, Maintains Hold Rating	MT
01/08	Wolfe Adjusts Price Target on ResMed to $215 From $200, Maintains Underperform Rating	MT
01/08	Mizuho Adjusts Price Target on ResMed to $290 From $270, Maintains Outperform Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	RESMED, INC.					+16.54%
	THERMO FISHER SCIENTIFIC, INC.					+9.16%
	INTUITIVE SURGICAL, INC.					+8.86%
	DANAHER CORPORATION					+10.21%
	BOSTON SCIENTIFIC CORPORATION					+37.86%
	SIEMENS HEALTHINEERS AG					+30.65%
	EDWARDS LIFESCIENCES CORPORATION					+13.43%
	AGILENT TECHNOLOGIES, INC.					+18.6%
	GE HEALTHCARE TECHNOLOGIES INC.					+3.2%
	SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.					+43.05%
	Average					+19.15%
	Weighted average by Cap.					+16.40%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

252.39USD

Average target price

294.13USD

Spread / Average Target

+16.54%

High Price Target

345.00USD

Spread / Highest target

+36.69%

Low Price Target

225.00USD

Spread / Lowest Target

-10.85%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Baird
Jefferies & Co.
Wells Fargo Securities
Wolfe Research
Morgan Stanley
Mizuho Securities
KeyBanc Capital Markets
RBC Capital Markets
Citigroup
CICC Research
UBS
JPMorgan Chase
Stifel Nicolaus
Piper Sandler
Jarden Research
Oppenheimer
Needham & Co.
Evans & Partners
BofA Securities
JMP Securities
Goldman Sachs
Macquarie
J.P. Morgan Chase